Zimmer Biomet Logo

PDF Download PDF    Print page    Email page    Add to Briefcase Add to briefcase
« Previous Release | Next Release »



Zimmer Holdings, Inc. Reports First Quarter 2015 Financial Results

WARSAW, Ind., April 30, 2015 /PRNewswire/ --

Zimmer Holdings, Inc. (NYSE and SIX: ZMH) today reported financial results for the quarter ended March 31, 2015. The Company reported first quarter net sales of $1.13 billion, a decrease of 2.3% reported and an increase of 4.5% constant currency compared to the first quarter of 2014.  Diluted earnings per share for the quarter were $1.02 reported and $1.58 adjusted, a decrease of 1.3% adjusted from the prior year period.

ZIMMER, INC. LOGO

"In the first quarter, Zimmer achieved steady sales growth in several geographies and product categories, while continuing to meet our financial commitments and deliver expanded operating margin leverage," said David Dvorak, President and CEO of Zimmer.  "Notably, we recently received approval from the European Commission and the Japan Fair Trade Commission for our pending combination with Biomet, which we now expect to close during the month of May, 2015.  This historic merger will enhance our leadership in musculoskeletal healthcare by drawing upon the talent and capabilities that have enabled the extraordinary growth and sustained success of our two companies."

Net earnings for the first quarter were $177.1 million on a reported basis and $272.8 million on an adjusted basis, a decrease of 0.6% adjusted from the prior year period.  Operating cash flow for the first quarter was $73.0 million, inclusive of a payment of $97.6 million to settle a pre-issuance hedge contract associated with the Company's recent senior notes offering. 

Also in the quarter, the Company paid $37.3 million in dividends and declared a first quarter dividend of $0.22 per share, consistent with the dividend declared for the prior year period.

Guidance

Based upon the continued strengthening of the U.S. dollar, the Company has updated its full-year 2015 standalone adjusted earnings guidance.  The Company now expects adjusted diluted earnings per share on a standalone basis to be in a range of $6.30 to $6.40.  This compares to prior full-year 2015 guidance of $6.50 to $6.60.  Additionally, changes in currency rates are also expected to negatively impact Biomet earnings, which the Company expects to be partially offset by greater synergies from the pending merger than had previously been contemplated in the Company's guidance.  Net annual operating earnings synergies connected with the pending merger are now anticipated to reach $350 million by year three following the closing of the transaction.  This compares to prior guidance of net annual synergies of $270 million by the third year post-closing.  Consequently, the Company now expects accretion from the pending merger with Biomet to contribute between $0.95 and $1.05 to adjusted diluted earnings per share in the first 12 months following the closing of the transaction.  This accretion guidance was previously a range of $1.05 to $1.15

Conference Call

The Company will conduct its first quarter 2015 investor conference call today, April 30, 2015, at 8:00 a.m. Eastern Time.  The live audio webcast can be accessed via Zimmer's Investor Relations website at http://investor.zimmer.com.  It will be archived for replay following the conference call.

Individuals in the U.S. and Canada who wish to dial into the conference call may do so by dialing (877) 941-1227 and entering conference ID 4696681.  For a complete listing of international toll-free and local numbers, please visit http://investor.zimmer.com.  A digital recording will be available 24 hours after the completion of the conference call, from May 1, 2015 to May 30, 2015.  To access the recording, U.S. and Canada callers should dial (800) 406-7325 and international callers should dial +1 (303) 590-3030, and enter the Access Code ID 4696670.

Sales Table

The following table provides sales results by geographic segment and product category, as well as the percentage change compared to the prior year quarter on both a reported and constant currency basis.

  

NET SALES - THREE MONTHS ENDED  MARCH 31, 2015


(in millions, unaudited)

































Constant




Net


Reported


Currency




Sales


 % Change


% Change

Geographic Segments











   Americas

$

645



1

%


2

%


   Europe


299



(9)



9



   Asia Pacific


190



(3)



7



       Total


1,134



(2)



5


Product Categories











Reconstructive











   Americas


478



1



2



   Europe


235



(8)



9



   Asia Pacific


139



(3)



7



       Total


852



(2)



5
















Knees












   Americas


295



4



5




   Europe


121



(8)



10




   Asia Pacific


72



(3)



7




       Total


488



-



6
















Hips












   Americas


145



(3)



(3)




   Europe


104



(10)



8




   Asia Pacific


63



(4)



7




       Total


312



(6)



3
















Extremities


52



-



5















Dental


56



(9)



(3)















Trauma


79



-



7















Spine


49



3



7















Surgical and other


98



(3)



3














 

About the Company

Founded in 1927, and headquartered in Warsaw, Indiana, Zimmer designs, develops, manufactures and markets orthopaedic reconstructive, spinal and trauma devices, dental implants, and related surgical products.  Zimmer has operations in more than 25 countries around the world and sells products in more than 100 countries.  Zimmer's 2014 sales were approximately $4.7 billion.  Zimmer is supported by the efforts of more than 9,000 employees worldwide.

Website Information

We routinely post important information for investors on our website, www.zimmer.com, in the "Investor Relations" section.  We use this website as a means of disclosing material, non-public information and for complying with our disclosure obligations under Regulation FD.  Accordingly, investors should monitor the Investor Relations section of our website, in addition to following our press releases, SEC filings, public conference calls, presentations and webcasts.  The information contained on, or that may be accessed through, our website is not incorporated by reference into, and is not a part of, this document.

Note on Non-GAAP Financial Measures and Updated Quarter Closing Convention

As used in this press release, the term "adjusted" refers to operating performance measures that exclude inventory step-up and other inventory and manufacturing related charges, special items, intangible asset amortization, financing and other expenses related to the pending Biomet merger and certain tax adjustments.  Included in special items are acquisition and integration costs and asset impairment charges related to prior and pending acquisitions, as well as employee termination benefits, consulting and professional fees, certain litigation matters, dedicated personnel expenses, certain contract terminations and asset impairment charges connected with global restructuring and operational excellence initiatives.  The term "constant currency" refers to any financial measure that excludes the effect of changes in foreign currency exchange rates.  Reconciliations of these non-GAAP measures to the most directly comparable GAAP measure are included in this press release.

Beginning with the three months ended March 31, 2015, the Company has changed its quarter-end closing convention for the majority of its international reporting units, which, in the case of the three months ended March 31, 2015, resulted in a change of that quarter-end close from March 25 to March 31.  As a consequence, our results of operations for the three months ended March 31, 2015 include up to four more billing days for such international reporting units than were included in our results of operations for the three months ended March 31, 2014.  The Company has not restated the presentation of the 2014 financial statements to conform to this change of closing convention because the impact of the change is not material to the results of operations or to the comparisons between the 2015 and 2014 periods.  

Cautionary Statement Regarding Forward-Looking Statements

This communication contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.  Forward-looking statements may be identified by the use of forward-looking terms such as "may," "will," "expects," "believes," "anticipates," "plans," "estimates," "projects," "assumes," "guides," "targets," "forecasts," and "seeks" or the negative of such terms or other variations on such terms or comparable terminology.  Such forward-looking statements include, but are not limited to, statements about the benefits of the proposed merger between Zimmer and LVB Acquisition, Inc. ("LVB"), the parent company of Biomet, including future financial and operating results, the combined company's plans, objectives, expectations and intentions, the expected timing of completion of the transaction and other statements that are not historical facts.  Such statements are based upon the current beliefs and expectations of Zimmer's management and are subject to significant risks and uncertainties that could cause actual outcomes and results to differ materially.  These risks and uncertainties include, but are not limited to: the possibility that the anticipated synergies and other benefits from the proposed merger of Zimmer and LVB will not be realized, or will not be realized within the expected time periods; the inability to obtain regulatory approvals of the merger (including the approval of antitrust authorities necessary to complete the transaction) on the terms desired or anticipated; the timing of such approvals and the risk that such approvals may result in the imposition of conditions that could adversely affect the combined company or the expected benefits of the transaction; the risk that a condition to closing the transaction may not be satisfied on a timely basis or at all; the risk that the proposed transaction fails to close for any other reason; the risks and uncertainties related to Zimmer's ability to successfully integrate the operations, products and employees of Zimmer and Biomet; the effect of the potential disruption of management's attention from ongoing business operations due to the pending merger; the effect of the announcement of the proposed merger on Zimmer's and Biomet's relationships with their respective customers, vendors and lenders and on their respective operating results and businesses generally; risks relating to the value of the Zimmer shares to be issued in the transaction; the outcome of any legal proceedings related to the proposed merger; the risks and uncertainties normally incidental to the orthopaedic industry, including price and product competition; the success of the companies' quality and operational excellence initiatives; changes in customer demand for Zimmer's or Biomet's products and services caused by demographic changes or other factors; the impact of healthcare reform measures, including the impact of the U.S. excise tax on medical devices; reductions in reimbursement levels by third-party payors and cost containment efforts of healthcare purchasing organizations; dependence on new product development, technological advances and innovation; shifts in the product category or regional sales mix of Zimmer's or Biomet's products and services; supply and prices of raw materials and products; control of costs and expenses; the ability to obtain and maintain adequate intellectual property protection; the ability to form and implement alliances; challenges relating to changes in and compliance with governmental laws and regulations, including regulations of the U.S. Food and Drug Administration (the "FDA") and foreign government regulators, such as more stringent requirements for regulatory clearance of products; the ability to remediate matters identified in any inspectional observations or warning letters issued by the FDA; changes in tax obligations arising from tax reform measures or examinations by tax authorities; product liability and intellectual property litigation losses; the ability to retain the independent agents and distributors who market Zimmer's and Biomet's products; dependence on a limited number of suppliers for key raw materials and outsourced activities; changes in general industry and market conditions, including domestic and international growth rates and general domestic and international economic conditions, including interest rate and currency exchange rate fluctuations; and the impact of the ongoing economic uncertainty affecting countries in the Euro zone on the ability to collect accounts receivable in affected countries.  For a further list and description of such risks and uncertainties, see Zimmer's periodic reports filed with the U.S. Securities and Exchange Commission (the "SEC").  Copies of these filings, as well as subsequent filings, are available online at www.sec.gov, www.zimmer.com or on request from Zimmer.  Zimmer disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be set forth in its periodic reports.  Readers of this communication are cautioned not to place undue reliance on these forward-looking statements, since, while management believes the assumptions on which the forward-looking statements are based are reasonable, there can be no assurance that these forward-looking statements will prove to be accurate.  This cautionary statement is applicable to all forward-looking statements contained in this communication.

Additional Information and Where to Find It

Zimmer filed with the SEC, and the SEC declared effective on September 29, 2014, a registration statement on Form S-4 that includes a consent solicitation statement of LVB that also constitutes a prospectus of Zimmer.  INVESTORS AND SECURITYHOLDERS OF LVB ARE URGED TO READ THE CONSENT SOLICITATION STATEMENT/PROSPECTUS AND OTHER FILINGS MADE WITH THE SEC IN CONNECTION WITH THE MERGER CAREFULLY AND IN THEIR ENTIRETY, BECAUSE THEY CONTAIN IMPORTANT INFORMATION ABOUT THE MERGER.  The registration statement and consent solicitation statement/prospectus and other documents filed by Zimmer with the SEC may be obtained free of charge at the SEC's website at www.sec.gov or from Zimmer at www.zimmer.com.  You may also read and copy any reports, statements and other information filed by Zimmer, LVB and Biomet with the SEC at the SEC public reference room at 100 F Street N.E., Room 1580, Washington, D.C. 20549.  Please call the SEC at (800) 732-0330 or visit the SEC's website for further information on its public reference room.  Certain executive officers and directors of LVB have interests in the proposed transaction that may differ from the interests of stockholders generally, including benefits conferred under retention, severance and change in control arrangements and continuation of director and officer insurance and indemnification.

This communication shall not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to appropriate registration or qualification under the securities laws of such jurisdiction.  No offering of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended.

 


 ZIMMER HOLDINGS, INC. 

 CONSOLIDATED STATEMENTS OF EARNINGS 

 FOR THE THREE MONTHS ENDED MARCH 31, 2015 and 2014 

 (in millions, except per share amounts, unaudited) 







2015


2014


 Net Sales 

$     1,134.4


$     1,161.5


 Cost of products sold 

278.7


303.7


 Gross Profit 

855.7


857.8







 Research and development 

48.4


47.4


 Selling, general and administrative 

425.0


444.5


 Intangible asset amortization 

20.4


29.2


 Special items 

87.0


36.6


      Operating expenses 

580.8


557.7







 Operating Profit 

274.9


300.1


 Other expense 

(22.6)


(1.7)


 Interest income 

2.6


2.5


 Interest expense 

(23.1)


(15.0)


 Earnings before income taxes  

231.8


285.9


 Provision for income taxes 

55.0


64.8


 Net earnings 

176.8


221.1


 Less:  Net loss attributable to noncontrolling interest 

(0.3)


(0.4)


 Net Earnings of Zimmer Holdings, Inc. 

$        177.1


$        221.5







 Earnings Per Common Share 





     Basic 

$          1.04


$          1.31


     Diluted 

$          1.02


$          1.29







 Weighted Average Common Shares Outstanding 





     Basic 

170.0


169.1


     Diluted 

172.9


171.8







 Cash dividends declared per common share 

$          0.22


$          0.22







 

 

 ZIMMER HOLDINGS, INC. 

 CONDENSED CONSOLIDATED BALANCE SHEETS 

 (in millions, unaudited) 






March 31,

December 31,





2015

2014

 Assets 






 Current Assets: 






   Cash and cash equivalents 




$            8,793.5

$            1,083.3

   Short-term investments 




488.4

612.5

   Receivables, net 




869.8

912.1

   Inventories 




1,217.0

1,169.0

   Other current assets 




548.5

512.1

       Total current assets 




11,917.2

4,289.0







 Property, plant and equipment, net 



1,300.7

1,288.8

 Goodwill 




2,417.0

2,514.2

 Intangible assets, net 




578.3

603.5

 Other assets 




976.9

939.2

 Total Assets 




$          17,190.1

$            9,634.7







 Liabilities and Stockholders' Equity 











 Current liabilities 




$               908.7

$            1,038.0

 Other long-term liabilities 




637.2

648.6

 Long-term debt 




9,061.2

1,425.5

 Stockholders' equity 




6,583.0

6,522.6

 Total Liabilities and Stockholders' Equity 


$          17,190.1

$            9,634.7







 

 

 ZIMMER HOLDINGS, INC. 

 CONSOLIDATED STATEMENTS OF CASH FLOWS 

 FOR THE THREE MONTHS ENDED MARCH 31, 2015 and 2014 

 (in millions, unaudited) 













2015

2014








 Cash flows provided by (used in) operating activities 





 Net earnings 




$        176.8

$        221.1


 Depreciation and amortization 




89.0

101.0


 Share-based compensation 




12.9

11.2


 Income tax benefits from employee stock compensation plans 


16.4

20.2


 Excess income tax benefits from employee stock compensation plans 


(7.8)

(5.4)


 Inventory step-up 




0.4

2.5


 Changes in operating assets and liabilities, net of acquired assets and liabilities 




     Income taxes 




(13.3)

(75.6)


     Receivables 




6.6

5.3


     Inventories 




(62.2)

(56.6)


     Accounts payable and accrued expenses 



(149.5)

(56.0)


     Other assets and liabilities 




22.2

21.1


 Net cash provided by operating activities 



91.5

188.8








 Cash flows provided by (used in) investing activities 





 Additions to instruments 




(62.4)

(49.4)


 Additions to other property, plant and equipment 


(34.4)

(31.4)


 Purchases of investments 




(152.6)

(600.7)


 Sales of investments 




320.3

583.1


 Investments in other assets 




(3.0)

-


 Net cash provided by (used in) investing activities 


67.9

(98.4)








 Cash flows provided by (used in) financing activities 





 Proceeds from senior notes 




7,628.2

-


 Net proceeds under revolving credit facilities 



0.8

0.2


 Dividends paid to stockholders 



(37.3)

(34.0)


 Proceeds from employee stock compensation plans 


27.5

138.2


 Excess income tax benefits from employee stock compensation plans 


7.8

5.4


 Debt issuance costs 




(58.4)

-


 Repurchase of common stock 




-

(400.5)


 Net cash provided by (used in) financing activities 


7,568.6

(290.7)








 Effect of exchange rates on cash and cash equivalents 


(17.8)

2.4









 Increase in cash and cash equivalents 



7,710.2

(197.9)

 Cash and cash equivalents, beginning of period 



1,083.3

1,080.6

 Cash and cash equivalents, end of period 



$     8,793.5

$        882.7

 

 ZIMMER HOLDINGS, INC. 

 NET SALES BY GEOGRAPHIC SEGMENT 

 FOR THE THREE MONTHS ENDED MARCH 31, 2015 and 2014 

 (in millions, unaudited) 



 Three Months Ended March 31







2015

2014

% Inc/(Dec)








 Americas 

$        645.2

$        638.7

1

%

 Europe 

298.9

326.9

(9)


 Asia Pacific 

190.3

195.9

(3)


 Total 

$     1,134.4

$     1,161.5

(2)








 

 ZIMMER HOLDINGS, INC. 

 NET SALES BY PRODUCT CATEGORY 

 FOR THE THREE MONTHS ENDED MARCH 31, 2015 and 2014 

 (in millions, unaudited) 



 Three Months Ended March 31







2015

2014

% Inc/(Dec)








 Reconstructive 






 Knees 

$        487.3

$        487.9

-

%


 Hips 

312.2

331.7

(6)



 Extremities 

52.2

52.1

-




851.7

871.7

(2)








 Dental 

55.8

61.0

(9)


 Trauma 

79.4

79.7

-


 Spine 

49.5

48.3

3


 Surgical and other 

98.0

100.8

(3)


 Total 

$     1,134.4

$     1,161.5

(2)








 

ZIMMER HOLDINGS, INC.

RECONCILIATION OF REPORTED % GROWTH TO

CONSTANT CURRENCY % GROWTH

(unaudited)



















For the Three Months Ended




March 31, 2015







Foreign


Constant




Reported


Exchange


Currency




% Change


Impact


% Change

Geographic Segments










   Americas

1

%


(1)

%


2

%


   Europe

(9)



(18)



9



   Asia Pacific

(3)



(10)



7



       Total

(2)



(7)



5


Product Categories










Reconstructive










   Americas

1



(1)



2



   Europe

(8)



(17)



9



   Asia Pacific

(3)



(10)



7



       Total

(2)



(7)



5















Knees











   Americas

4



(1)



5




   Europe

(8)



(18)



10




   Asia Pacific

(3)



(10)



7




       Total

-



(6)



6















Hips











   Americas

(3)



-



(3)




   Europe

(10)



(18)



8




   Asia Pacific

(4)



(11)



7




       Total

(6)



(9)



3















Extremities

-



(5)



5














Dental

(9)



(6)



(3)














Trauma

-



(7)



7














Spine

3



(4)



7














Surgical and other

(3)



(6)



3













 

 ZIMMER HOLDINGS, INC. 

 Reconciliation of Net Earnings and Adjusted Net Earnings 

 For the Three Months Ended March 31, 2015 and 2014 

 (in millions, unaudited) 








 Three Months 



 Ended March 31



2015


2014






 Net Earnings of Zimmer Holdings, Inc. 

$       177.1


$       221.5

 Inventory step-up and other inventory  




    and manufacturing related charges 

3.9


11.7

 Intangible asset amortization 

20.4


29.2

 Special items 


87.0


36.6

 Other expense on Biomet merger financing 

19.5


-

 Interest expense on Biomet merger financing 

8.5


-

 Taxes on above items* 

(43.6)


(24.5)

 Adjusted Net Earnings 

$       272.8


$       274.5






 * The tax effect is calculated based upon the statutory rates for the jurisdictions where the items 

    were incurred. 




 

 ZIMMER HOLDINGS, INC. 

 Reconciliation of Diluted EPS and Adjusted Diluted EPS 

 For the Three Months Ended March 31, 2015 and 2014 

 (unaudited) 








 Three Months 



 Ended March 31,  



2015


2014






 Diluted EPS 


$         1.02


$         1.29

 Inventory step-up and other inventory  




    and manufacturing related charges 

0.02


0.07

 Intangible asset amortization 

0.12


0.17

 Special items 


0.51


0.21

 Other expense on Biomet merger financing 

0.11


-

 Interest expense on Biomet merger financing 

0.05


-

 Taxes on above items* 

(0.25)


(0.14)

 Adjusted Diluted EPS 

$         1.58


$         1.60






 * The tax effect is calculated based upon the statutory rates for the jurisdictions where the items 

    were incurred. 




 

Logo - http://photos.prnewswire.com/prnh/20131216/MM33947LOGO

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/zimmer-holdings-inc-reports-first-quarter-2015-financial-results-300074727.html

SOURCE Zimmer Holdings, Inc.

News Provided by Acquire Media

Close window | Back to top